Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors
CONTEXT AND OBJECTIVE: Genetic investigation of central nervous system (CNS) tumors provides valuable information about the genes regulating proliferation, differentiation, angiogenesis, migration and apoptosis in the CNS. The aim of our study was to determine the prevalence of genetic polymorphisms...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Mev Dominguez Valentin [verfasserIn] Renata Canalle [verfasserIn] Rosane de Paula Queiroz [verfasserIn] Luiz Gonzaga Tone [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Schlagwörter: |
Cyclin-dependent kinase inhibitor p21 |
|---|
| Übergeordnetes Werk: |
In: São Paulo Medical Journal - Associação Paulista de Medicina, 2016 |
|---|
| Links: |
|---|
| DOI / URN: |
10.1590/S1516-31802009000500008 |
|---|
| Katalog-ID: |
DOAJ04257319X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ04257319X | ||
| 003 | DE-627 | ||
| 005 | 20230308062550.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227nuuuuuuuuxx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1590/S1516-31802009000500008 |2 doi | |
| 035 | |a (DE-627)DOAJ04257319X | ||
| 035 | |a (DE-599)DOAJ84186866ea894cb8aefbd2a5cd779a30 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Mev Dominguez Valentin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a CONTEXT AND OBJECTIVE: Genetic investigation of central nervous system (CNS) tumors provides valuable information about the genes regulating proliferation, differentiation, angiogenesis, migration and apoptosis in the CNS. The aim of our study was to determine the prevalence of genetic polymorphisms (codon 31 and 3' untranslated region, 3'UTR) and protein expression of the cyclin-dependent kinase inhibitor 1A (CDKN1A) gene in patients with and without CNS tumors. DESIGN AND SETTING: Analytical cross-sectional study with a control group, at the Molecular Biology Laboratory, Pediatric Oncology Department, Hospital das Clínicas de Ribeirão Preto. METHODS: 41 patients with CNS tumors and a control group of 161 subjects without cancer and paires for sex, age and ethnicity were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Protein analysis was performed on 36 patients with CNS tumors, using the Western Blotting technique. RESULTS: The frequencies of the heterozygote (Ser/Arg) and polymorphic homozygote (Arg/Arg) genotypes of codon 31 in the control subjects were 28.0% and 1.2%, respectively. However, the 3'UTR site presented frequencies of 24.2% (C/T) and 0.6% (T/T). These frequencies were not statistically different (P < 0.05) from those seen in the patients with CNS tumors (19.4% and 0.0%, codon 31; 15.8% and 2.6%, 3'UTR site). Regarding the protein expression in ependymomas, 66.67% did not express the protein CDKN1A. The results for medulloblastomas and astrocytomas were similar: neither of them expressed the protein (57.14% and 61.54%, respectively). CONCLUSION: No significant differences in protein expression patterns or polymorphisms of CDKN1A in relation to the three types of CNS tumors were observed among Brazilian subjects. | ||
| 650 | 4 | |a Cyclin-dependent kinase inhibitor p21 | |
| 650 | 4 | |a Brain neoplasms | |
| 650 | 4 | |a Polymorphism, genetic | |
| 650 | 4 | |a Polymorphism, restriction fragment length | |
| 650 | 4 | |a Blotting, western | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Renata Canalle |e verfasserin |4 aut | |
| 700 | 0 | |a Rosane de Paula Queiroz |e verfasserin |4 aut | |
| 700 | 0 | |a Luiz Gonzaga Tone |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t São Paulo Medical Journal |d Associação Paulista de Medicina, 2016 |w (DE-627)324825102 |w (DE-600)2031087-0 |x 18069460 |7 nnns |
| 856 | 4 | 0 | |u https://doi.org/10.1590/S1516-31802009000500008 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/84186866ea894cb8aefbd2a5cd779a30 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802009000500008&lng=en&tlng=en |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1806-9460 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| author_variant |
m d v mdv r c rc r d p q rdpq l g t lgt |
|---|---|
| matchkey_str |
article:18069460:uuuuuuuu::rqecoplmrhssnpoenxrsinfylneednknsihbtradna |
| allfields |
10.1590/S1516-31802009000500008 doi (DE-627)DOAJ04257319X (DE-599)DOAJ84186866ea894cb8aefbd2a5cd779a30 DE-627 ger DE-627 rakwb eng Mev Dominguez Valentin verfasserin aut Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier CONTEXT AND OBJECTIVE: Genetic investigation of central nervous system (CNS) tumors provides valuable information about the genes regulating proliferation, differentiation, angiogenesis, migration and apoptosis in the CNS. The aim of our study was to determine the prevalence of genetic polymorphisms (codon 31 and 3' untranslated region, 3'UTR) and protein expression of the cyclin-dependent kinase inhibitor 1A (CDKN1A) gene in patients with and without CNS tumors. DESIGN AND SETTING: Analytical cross-sectional study with a control group, at the Molecular Biology Laboratory, Pediatric Oncology Department, Hospital das Clínicas de Ribeirão Preto. METHODS: 41 patients with CNS tumors and a control group of 161 subjects without cancer and paires for sex, age and ethnicity were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Protein analysis was performed on 36 patients with CNS tumors, using the Western Blotting technique. RESULTS: The frequencies of the heterozygote (Ser/Arg) and polymorphic homozygote (Arg/Arg) genotypes of codon 31 in the control subjects were 28.0% and 1.2%, respectively. However, the 3'UTR site presented frequencies of 24.2% (C/T) and 0.6% (T/T). These frequencies were not statistically different (P < 0.05) from those seen in the patients with CNS tumors (19.4% and 0.0%, codon 31; 15.8% and 2.6%, 3'UTR site). Regarding the protein expression in ependymomas, 66.67% did not express the protein CDKN1A. The results for medulloblastomas and astrocytomas were similar: neither of them expressed the protein (57.14% and 61.54%, respectively). CONCLUSION: No significant differences in protein expression patterns or polymorphisms of CDKN1A in relation to the three types of CNS tumors were observed among Brazilian subjects. Cyclin-dependent kinase inhibitor p21 Brain neoplasms Polymorphism, genetic Polymorphism, restriction fragment length Blotting, western Medicine R Renata Canalle verfasserin aut Rosane de Paula Queiroz verfasserin aut Luiz Gonzaga Tone verfasserin aut In São Paulo Medical Journal Associação Paulista de Medicina, 2016 (DE-627)324825102 (DE-600)2031087-0 18069460 nnns https://doi.org/10.1590/S1516-31802009000500008 kostenfrei https://doaj.org/article/84186866ea894cb8aefbd2a5cd779a30 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802009000500008&lng=en&tlng=en kostenfrei https://doaj.org/toc/1806-9460 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR |
| spelling |
10.1590/S1516-31802009000500008 doi (DE-627)DOAJ04257319X (DE-599)DOAJ84186866ea894cb8aefbd2a5cd779a30 DE-627 ger DE-627 rakwb eng Mev Dominguez Valentin verfasserin aut Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier CONTEXT AND OBJECTIVE: Genetic investigation of central nervous system (CNS) tumors provides valuable information about the genes regulating proliferation, differentiation, angiogenesis, migration and apoptosis in the CNS. The aim of our study was to determine the prevalence of genetic polymorphisms (codon 31 and 3' untranslated region, 3'UTR) and protein expression of the cyclin-dependent kinase inhibitor 1A (CDKN1A) gene in patients with and without CNS tumors. DESIGN AND SETTING: Analytical cross-sectional study with a control group, at the Molecular Biology Laboratory, Pediatric Oncology Department, Hospital das Clínicas de Ribeirão Preto. METHODS: 41 patients with CNS tumors and a control group of 161 subjects without cancer and paires for sex, age and ethnicity were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Protein analysis was performed on 36 patients with CNS tumors, using the Western Blotting technique. RESULTS: The frequencies of the heterozygote (Ser/Arg) and polymorphic homozygote (Arg/Arg) genotypes of codon 31 in the control subjects were 28.0% and 1.2%, respectively. However, the 3'UTR site presented frequencies of 24.2% (C/T) and 0.6% (T/T). These frequencies were not statistically different (P < 0.05) from those seen in the patients with CNS tumors (19.4% and 0.0%, codon 31; 15.8% and 2.6%, 3'UTR site). Regarding the protein expression in ependymomas, 66.67% did not express the protein CDKN1A. The results for medulloblastomas and astrocytomas were similar: neither of them expressed the protein (57.14% and 61.54%, respectively). CONCLUSION: No significant differences in protein expression patterns or polymorphisms of CDKN1A in relation to the three types of CNS tumors were observed among Brazilian subjects. Cyclin-dependent kinase inhibitor p21 Brain neoplasms Polymorphism, genetic Polymorphism, restriction fragment length Blotting, western Medicine R Renata Canalle verfasserin aut Rosane de Paula Queiroz verfasserin aut Luiz Gonzaga Tone verfasserin aut In São Paulo Medical Journal Associação Paulista de Medicina, 2016 (DE-627)324825102 (DE-600)2031087-0 18069460 nnns https://doi.org/10.1590/S1516-31802009000500008 kostenfrei https://doaj.org/article/84186866ea894cb8aefbd2a5cd779a30 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802009000500008&lng=en&tlng=en kostenfrei https://doaj.org/toc/1806-9460 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR |
| allfields_unstemmed |
10.1590/S1516-31802009000500008 doi (DE-627)DOAJ04257319X (DE-599)DOAJ84186866ea894cb8aefbd2a5cd779a30 DE-627 ger DE-627 rakwb eng Mev Dominguez Valentin verfasserin aut Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier CONTEXT AND OBJECTIVE: Genetic investigation of central nervous system (CNS) tumors provides valuable information about the genes regulating proliferation, differentiation, angiogenesis, migration and apoptosis in the CNS. The aim of our study was to determine the prevalence of genetic polymorphisms (codon 31 and 3' untranslated region, 3'UTR) and protein expression of the cyclin-dependent kinase inhibitor 1A (CDKN1A) gene in patients with and without CNS tumors. DESIGN AND SETTING: Analytical cross-sectional study with a control group, at the Molecular Biology Laboratory, Pediatric Oncology Department, Hospital das Clínicas de Ribeirão Preto. METHODS: 41 patients with CNS tumors and a control group of 161 subjects without cancer and paires for sex, age and ethnicity were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Protein analysis was performed on 36 patients with CNS tumors, using the Western Blotting technique. RESULTS: The frequencies of the heterozygote (Ser/Arg) and polymorphic homozygote (Arg/Arg) genotypes of codon 31 in the control subjects were 28.0% and 1.2%, respectively. However, the 3'UTR site presented frequencies of 24.2% (C/T) and 0.6% (T/T). These frequencies were not statistically different (P < 0.05) from those seen in the patients with CNS tumors (19.4% and 0.0%, codon 31; 15.8% and 2.6%, 3'UTR site). Regarding the protein expression in ependymomas, 66.67% did not express the protein CDKN1A. The results for medulloblastomas and astrocytomas were similar: neither of them expressed the protein (57.14% and 61.54%, respectively). CONCLUSION: No significant differences in protein expression patterns or polymorphisms of CDKN1A in relation to the three types of CNS tumors were observed among Brazilian subjects. Cyclin-dependent kinase inhibitor p21 Brain neoplasms Polymorphism, genetic Polymorphism, restriction fragment length Blotting, western Medicine R Renata Canalle verfasserin aut Rosane de Paula Queiroz verfasserin aut Luiz Gonzaga Tone verfasserin aut In São Paulo Medical Journal Associação Paulista de Medicina, 2016 (DE-627)324825102 (DE-600)2031087-0 18069460 nnns https://doi.org/10.1590/S1516-31802009000500008 kostenfrei https://doaj.org/article/84186866ea894cb8aefbd2a5cd779a30 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802009000500008&lng=en&tlng=en kostenfrei https://doaj.org/toc/1806-9460 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR |
| allfieldsGer |
10.1590/S1516-31802009000500008 doi (DE-627)DOAJ04257319X (DE-599)DOAJ84186866ea894cb8aefbd2a5cd779a30 DE-627 ger DE-627 rakwb eng Mev Dominguez Valentin verfasserin aut Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier CONTEXT AND OBJECTIVE: Genetic investigation of central nervous system (CNS) tumors provides valuable information about the genes regulating proliferation, differentiation, angiogenesis, migration and apoptosis in the CNS. The aim of our study was to determine the prevalence of genetic polymorphisms (codon 31 and 3' untranslated region, 3'UTR) and protein expression of the cyclin-dependent kinase inhibitor 1A (CDKN1A) gene in patients with and without CNS tumors. DESIGN AND SETTING: Analytical cross-sectional study with a control group, at the Molecular Biology Laboratory, Pediatric Oncology Department, Hospital das Clínicas de Ribeirão Preto. METHODS: 41 patients with CNS tumors and a control group of 161 subjects without cancer and paires for sex, age and ethnicity were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Protein analysis was performed on 36 patients with CNS tumors, using the Western Blotting technique. RESULTS: The frequencies of the heterozygote (Ser/Arg) and polymorphic homozygote (Arg/Arg) genotypes of codon 31 in the control subjects were 28.0% and 1.2%, respectively. However, the 3'UTR site presented frequencies of 24.2% (C/T) and 0.6% (T/T). These frequencies were not statistically different (P < 0.05) from those seen in the patients with CNS tumors (19.4% and 0.0%, codon 31; 15.8% and 2.6%, 3'UTR site). Regarding the protein expression in ependymomas, 66.67% did not express the protein CDKN1A. The results for medulloblastomas and astrocytomas were similar: neither of them expressed the protein (57.14% and 61.54%, respectively). CONCLUSION: No significant differences in protein expression patterns or polymorphisms of CDKN1A in relation to the three types of CNS tumors were observed among Brazilian subjects. Cyclin-dependent kinase inhibitor p21 Brain neoplasms Polymorphism, genetic Polymorphism, restriction fragment length Blotting, western Medicine R Renata Canalle verfasserin aut Rosane de Paula Queiroz verfasserin aut Luiz Gonzaga Tone verfasserin aut In São Paulo Medical Journal Associação Paulista de Medicina, 2016 (DE-627)324825102 (DE-600)2031087-0 18069460 nnns https://doi.org/10.1590/S1516-31802009000500008 kostenfrei https://doaj.org/article/84186866ea894cb8aefbd2a5cd779a30 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802009000500008&lng=en&tlng=en kostenfrei https://doaj.org/toc/1806-9460 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR |
| allfieldsSound |
10.1590/S1516-31802009000500008 doi (DE-627)DOAJ04257319X (DE-599)DOAJ84186866ea894cb8aefbd2a5cd779a30 DE-627 ger DE-627 rakwb eng Mev Dominguez Valentin verfasserin aut Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier CONTEXT AND OBJECTIVE: Genetic investigation of central nervous system (CNS) tumors provides valuable information about the genes regulating proliferation, differentiation, angiogenesis, migration and apoptosis in the CNS. The aim of our study was to determine the prevalence of genetic polymorphisms (codon 31 and 3' untranslated region, 3'UTR) and protein expression of the cyclin-dependent kinase inhibitor 1A (CDKN1A) gene in patients with and without CNS tumors. DESIGN AND SETTING: Analytical cross-sectional study with a control group, at the Molecular Biology Laboratory, Pediatric Oncology Department, Hospital das Clínicas de Ribeirão Preto. METHODS: 41 patients with CNS tumors and a control group of 161 subjects without cancer and paires for sex, age and ethnicity were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Protein analysis was performed on 36 patients with CNS tumors, using the Western Blotting technique. RESULTS: The frequencies of the heterozygote (Ser/Arg) and polymorphic homozygote (Arg/Arg) genotypes of codon 31 in the control subjects were 28.0% and 1.2%, respectively. However, the 3'UTR site presented frequencies of 24.2% (C/T) and 0.6% (T/T). These frequencies were not statistically different (P < 0.05) from those seen in the patients with CNS tumors (19.4% and 0.0%, codon 31; 15.8% and 2.6%, 3'UTR site). Regarding the protein expression in ependymomas, 66.67% did not express the protein CDKN1A. The results for medulloblastomas and astrocytomas were similar: neither of them expressed the protein (57.14% and 61.54%, respectively). CONCLUSION: No significant differences in protein expression patterns or polymorphisms of CDKN1A in relation to the three types of CNS tumors were observed among Brazilian subjects. Cyclin-dependent kinase inhibitor p21 Brain neoplasms Polymorphism, genetic Polymorphism, restriction fragment length Blotting, western Medicine R Renata Canalle verfasserin aut Rosane de Paula Queiroz verfasserin aut Luiz Gonzaga Tone verfasserin aut In São Paulo Medical Journal Associação Paulista de Medicina, 2016 (DE-627)324825102 (DE-600)2031087-0 18069460 nnns https://doi.org/10.1590/S1516-31802009000500008 kostenfrei https://doaj.org/article/84186866ea894cb8aefbd2a5cd779a30 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802009000500008&lng=en&tlng=en kostenfrei https://doaj.org/toc/1806-9460 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR |
| language |
English |
| source |
In São Paulo Medical Journal |
| sourceStr |
In São Paulo Medical Journal |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Cyclin-dependent kinase inhibitor p21 Brain neoplasms Polymorphism, genetic Polymorphism, restriction fragment length Blotting, western Medicine R |
| isfreeaccess_bool |
true |
| container_title |
São Paulo Medical Journal |
| authorswithroles_txt_mv |
Mev Dominguez Valentin @@aut@@ Renata Canalle @@aut@@ Rosane de Paula Queiroz @@aut@@ Luiz Gonzaga Tone @@aut@@ |
| publishDateDaySort_date |
2024-01-01T00:00:00Z |
| hierarchy_top_id |
324825102 |
| id |
DOAJ04257319X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ04257319X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308062550.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227nuuuuuuuuxx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1590/S1516-31802009000500008</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ04257319X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ84186866ea894cb8aefbd2a5cd779a30</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Mev Dominguez Valentin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">CONTEXT AND OBJECTIVE: Genetic investigation of central nervous system (CNS) tumors provides valuable information about the genes regulating proliferation, differentiation, angiogenesis, migration and apoptosis in the CNS. The aim of our study was to determine the prevalence of genetic polymorphisms (codon 31 and 3' untranslated region, 3'UTR) and protein expression of the cyclin-dependent kinase inhibitor 1A (CDKN1A) gene in patients with and without CNS tumors. DESIGN AND SETTING: Analytical cross-sectional study with a control group, at the Molecular Biology Laboratory, Pediatric Oncology Department, Hospital das Clínicas de Ribeirão Preto. METHODS: 41 patients with CNS tumors and a control group of 161 subjects without cancer and paires for sex, age and ethnicity were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Protein analysis was performed on 36 patients with CNS tumors, using the Western Blotting technique. RESULTS: The frequencies of the heterozygote (Ser/Arg) and polymorphic homozygote (Arg/Arg) genotypes of codon 31 in the control subjects were 28.0% and 1.2%, respectively. However, the 3'UTR site presented frequencies of 24.2% (C/T) and 0.6% (T/T). These frequencies were not statistically different (P < 0.05) from those seen in the patients with CNS tumors (19.4% and 0.0%, codon 31; 15.8% and 2.6%, 3'UTR site). Regarding the protein expression in ependymomas, 66.67% did not express the protein CDKN1A. The results for medulloblastomas and astrocytomas were similar: neither of them expressed the protein (57.14% and 61.54%, respectively). CONCLUSION: No significant differences in protein expression patterns or polymorphisms of CDKN1A in relation to the three types of CNS tumors were observed among Brazilian subjects.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cyclin-dependent kinase inhibitor p21</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Brain neoplasms</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Polymorphism, genetic</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Polymorphism, restriction fragment length</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Blotting, western</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Renata Canalle</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rosane de Paula Queiroz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luiz Gonzaga Tone</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">São Paulo Medical Journal</subfield><subfield code="d">Associação Paulista de Medicina, 2016</subfield><subfield code="w">(DE-627)324825102</subfield><subfield code="w">(DE-600)2031087-0</subfield><subfield code="x">18069460</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1590/S1516-31802009000500008</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/84186866ea894cb8aefbd2a5cd779a30</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802009000500008&lng=en&tlng=en</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1806-9460</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield></record></collection>
|
| author |
Mev Dominguez Valentin |
| spellingShingle |
Mev Dominguez Valentin misc Cyclin-dependent kinase inhibitor p21 misc Brain neoplasms misc Polymorphism, genetic misc Polymorphism, restriction fragment length misc Blotting, western misc Medicine misc R Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors |
| authorStr |
Mev Dominguez Valentin |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)324825102 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
18069460 |
| topic_title |
Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors Cyclin-dependent kinase inhibitor p21 Brain neoplasms Polymorphism, genetic Polymorphism, restriction fragment length Blotting, western |
| topic |
misc Cyclin-dependent kinase inhibitor p21 misc Brain neoplasms misc Polymorphism, genetic misc Polymorphism, restriction fragment length misc Blotting, western misc Medicine misc R |
| topic_unstemmed |
misc Cyclin-dependent kinase inhibitor p21 misc Brain neoplasms misc Polymorphism, genetic misc Polymorphism, restriction fragment length misc Blotting, western misc Medicine misc R |
| topic_browse |
misc Cyclin-dependent kinase inhibitor p21 misc Brain neoplasms misc Polymorphism, genetic misc Polymorphism, restriction fragment length misc Blotting, western misc Medicine misc R |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
São Paulo Medical Journal |
| hierarchy_parent_id |
324825102 |
| hierarchy_top_title |
São Paulo Medical Journal |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)324825102 (DE-600)2031087-0 |
| title |
Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors |
| ctrlnum |
(DE-627)DOAJ04257319X (DE-599)DOAJ84186866ea894cb8aefbd2a5cd779a30 |
| title_full |
Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors |
| author_sort |
Mev Dominguez Valentin |
| journal |
São Paulo Medical Journal |
| journalStr |
São Paulo Medical Journal |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| contenttype_str_mv |
txt |
| author_browse |
Mev Dominguez Valentin Renata Canalle Rosane de Paula Queiroz Luiz Gonzaga Tone |
| format_se |
Elektronische Aufsätze |
| author-letter |
Mev Dominguez Valentin |
| doi_str_mv |
10.1590/S1516-31802009000500008 |
| author2-role |
verfasserin |
| title_sort |
frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1a (cdkn1a) in central nervous system tumors |
| title_auth |
Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors |
| abstract |
CONTEXT AND OBJECTIVE: Genetic investigation of central nervous system (CNS) tumors provides valuable information about the genes regulating proliferation, differentiation, angiogenesis, migration and apoptosis in the CNS. The aim of our study was to determine the prevalence of genetic polymorphisms (codon 31 and 3' untranslated region, 3'UTR) and protein expression of the cyclin-dependent kinase inhibitor 1A (CDKN1A) gene in patients with and without CNS tumors. DESIGN AND SETTING: Analytical cross-sectional study with a control group, at the Molecular Biology Laboratory, Pediatric Oncology Department, Hospital das Clínicas de Ribeirão Preto. METHODS: 41 patients with CNS tumors and a control group of 161 subjects without cancer and paires for sex, age and ethnicity were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Protein analysis was performed on 36 patients with CNS tumors, using the Western Blotting technique. RESULTS: The frequencies of the heterozygote (Ser/Arg) and polymorphic homozygote (Arg/Arg) genotypes of codon 31 in the control subjects were 28.0% and 1.2%, respectively. However, the 3'UTR site presented frequencies of 24.2% (C/T) and 0.6% (T/T). These frequencies were not statistically different (P < 0.05) from those seen in the patients with CNS tumors (19.4% and 0.0%, codon 31; 15.8% and 2.6%, 3'UTR site). Regarding the protein expression in ependymomas, 66.67% did not express the protein CDKN1A. The results for medulloblastomas and astrocytomas were similar: neither of them expressed the protein (57.14% and 61.54%, respectively). CONCLUSION: No significant differences in protein expression patterns or polymorphisms of CDKN1A in relation to the three types of CNS tumors were observed among Brazilian subjects. |
| abstractGer |
CONTEXT AND OBJECTIVE: Genetic investigation of central nervous system (CNS) tumors provides valuable information about the genes regulating proliferation, differentiation, angiogenesis, migration and apoptosis in the CNS. The aim of our study was to determine the prevalence of genetic polymorphisms (codon 31 and 3' untranslated region, 3'UTR) and protein expression of the cyclin-dependent kinase inhibitor 1A (CDKN1A) gene in patients with and without CNS tumors. DESIGN AND SETTING: Analytical cross-sectional study with a control group, at the Molecular Biology Laboratory, Pediatric Oncology Department, Hospital das Clínicas de Ribeirão Preto. METHODS: 41 patients with CNS tumors and a control group of 161 subjects without cancer and paires for sex, age and ethnicity were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Protein analysis was performed on 36 patients with CNS tumors, using the Western Blotting technique. RESULTS: The frequencies of the heterozygote (Ser/Arg) and polymorphic homozygote (Arg/Arg) genotypes of codon 31 in the control subjects were 28.0% and 1.2%, respectively. However, the 3'UTR site presented frequencies of 24.2% (C/T) and 0.6% (T/T). These frequencies were not statistically different (P < 0.05) from those seen in the patients with CNS tumors (19.4% and 0.0%, codon 31; 15.8% and 2.6%, 3'UTR site). Regarding the protein expression in ependymomas, 66.67% did not express the protein CDKN1A. The results for medulloblastomas and astrocytomas were similar: neither of them expressed the protein (57.14% and 61.54%, respectively). CONCLUSION: No significant differences in protein expression patterns or polymorphisms of CDKN1A in relation to the three types of CNS tumors were observed among Brazilian subjects. |
| abstract_unstemmed |
CONTEXT AND OBJECTIVE: Genetic investigation of central nervous system (CNS) tumors provides valuable information about the genes regulating proliferation, differentiation, angiogenesis, migration and apoptosis in the CNS. The aim of our study was to determine the prevalence of genetic polymorphisms (codon 31 and 3' untranslated region, 3'UTR) and protein expression of the cyclin-dependent kinase inhibitor 1A (CDKN1A) gene in patients with and without CNS tumors. DESIGN AND SETTING: Analytical cross-sectional study with a control group, at the Molecular Biology Laboratory, Pediatric Oncology Department, Hospital das Clínicas de Ribeirão Preto. METHODS: 41 patients with CNS tumors and a control group of 161 subjects without cancer and paires for sex, age and ethnicity were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Protein analysis was performed on 36 patients with CNS tumors, using the Western Blotting technique. RESULTS: The frequencies of the heterozygote (Ser/Arg) and polymorphic homozygote (Arg/Arg) genotypes of codon 31 in the control subjects were 28.0% and 1.2%, respectively. However, the 3'UTR site presented frequencies of 24.2% (C/T) and 0.6% (T/T). These frequencies were not statistically different (P < 0.05) from those seen in the patients with CNS tumors (19.4% and 0.0%, codon 31; 15.8% and 2.6%, 3'UTR site). Regarding the protein expression in ependymomas, 66.67% did not express the protein CDKN1A. The results for medulloblastomas and astrocytomas were similar: neither of them expressed the protein (57.14% and 61.54%, respectively). CONCLUSION: No significant differences in protein expression patterns or polymorphisms of CDKN1A in relation to the three types of CNS tumors were observed among Brazilian subjects. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| title_short |
Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors |
| url |
https://doi.org/10.1590/S1516-31802009000500008 https://doaj.org/article/84186866ea894cb8aefbd2a5cd779a30 http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802009000500008&lng=en&tlng=en https://doaj.org/toc/1806-9460 |
| remote_bool |
true |
| author2 |
Renata Canalle Rosane de Paula Queiroz Luiz Gonzaga Tone |
| author2Str |
Renata Canalle Rosane de Paula Queiroz Luiz Gonzaga Tone |
| ppnlink |
324825102 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1590/S1516-31802009000500008 |
| up_date |
2024-07-04T01:27:48.623Z |
| _version_ |
1803609931643879424 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ04257319X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308062550.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227nuuuuuuuuxx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1590/S1516-31802009000500008</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ04257319X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ84186866ea894cb8aefbd2a5cd779a30</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Mev Dominguez Valentin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">CONTEXT AND OBJECTIVE: Genetic investigation of central nervous system (CNS) tumors provides valuable information about the genes regulating proliferation, differentiation, angiogenesis, migration and apoptosis in the CNS. The aim of our study was to determine the prevalence of genetic polymorphisms (codon 31 and 3' untranslated region, 3'UTR) and protein expression of the cyclin-dependent kinase inhibitor 1A (CDKN1A) gene in patients with and without CNS tumors. DESIGN AND SETTING: Analytical cross-sectional study with a control group, at the Molecular Biology Laboratory, Pediatric Oncology Department, Hospital das Clínicas de Ribeirão Preto. METHODS: 41 patients with CNS tumors and a control group of 161 subjects without cancer and paires for sex, age and ethnicity were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Protein analysis was performed on 36 patients with CNS tumors, using the Western Blotting technique. RESULTS: The frequencies of the heterozygote (Ser/Arg) and polymorphic homozygote (Arg/Arg) genotypes of codon 31 in the control subjects were 28.0% and 1.2%, respectively. However, the 3'UTR site presented frequencies of 24.2% (C/T) and 0.6% (T/T). These frequencies were not statistically different (P < 0.05) from those seen in the patients with CNS tumors (19.4% and 0.0%, codon 31; 15.8% and 2.6%, 3'UTR site). Regarding the protein expression in ependymomas, 66.67% did not express the protein CDKN1A. The results for medulloblastomas and astrocytomas were similar: neither of them expressed the protein (57.14% and 61.54%, respectively). CONCLUSION: No significant differences in protein expression patterns or polymorphisms of CDKN1A in relation to the three types of CNS tumors were observed among Brazilian subjects.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cyclin-dependent kinase inhibitor p21</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Brain neoplasms</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Polymorphism, genetic</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Polymorphism, restriction fragment length</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Blotting, western</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Renata Canalle</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rosane de Paula Queiroz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luiz Gonzaga Tone</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">São Paulo Medical Journal</subfield><subfield code="d">Associação Paulista de Medicina, 2016</subfield><subfield code="w">(DE-627)324825102</subfield><subfield code="w">(DE-600)2031087-0</subfield><subfield code="x">18069460</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1590/S1516-31802009000500008</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/84186866ea894cb8aefbd2a5cd779a30</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802009000500008&lng=en&tlng=en</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1806-9460</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield></record></collection>
|
| score |
7.400259 |